C4 local brand_plan_zelmac2

1

STRICTLY CONFIDENTIAL

Brand Name: Zelmac®Country:Middle East ( KSA, RO Gulf, RO Levant)C4 Local Brand Plan 2004Lite Deck, CEMEA Version

Confidential

2

C4 Insights Summary

C4 Local Brand Plan “Roadmap”

Executive SummaryMarket

Analysis & SWOT

Marketing Mix & Execution

Sales, Investment, Brand ROI

Key Issues

Key Messages & A-B Shift

Brand Strategy

KPI’s

Confidential

3

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

42

Zelnorm C4 Brand Plan – Executive Summary

• Vision

• Establish, grow and sustain market leadership in GI disorders including IBS, CC, Dyspepsia and GERD* (combination treatment)

• Positioning

In IBS-C, Zelmac is the most effective first line Rx treatment for abdominal pain, bloating, constipation (ABCs) because it is the only

drug that regulates motility, visceral sensitivity, and intestinal secretion throughout the GI tract

Confidential

5

Zelnorm C4 Brand Plan – Executive Summary

• Brand Strategy

• Symptom based approach to rapidly penetrate & expand several IBS markets in the ME region

• Ensure a positive re-enforcement by GI segment

• Expand to “potential “ PCP and help diagnose

• Invest in patient education and utilize PR to familiarize public with the condition and availability of new treatment

• Top activities in 04/05

• Launch to PCP audience in all ME markets

• Build KOL base by involving them in PCP education and PR activities

• Ensure an disease education and PR coverage on brand create a call for action at patient level

Confidential

6

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

7

Private Market IBS: Total ME Value 26.086 (000) USD Growth:+10.2%

0

2,000

4,000

6,000

8,000

10,000

12,000

14,000

2002 2003 2004(est.)

KSA

UAE

Leb

Jor

Confidential

8

Market Overview

• From limited market research in the area and focus groups conducted in 2003/2004

• We are aware that:

• IBS is the number #1 condition for visits at the GI clinic

• Doctors do not consider the syndrome as “serious”

• A diagnosis of exclusion is used in most cases rather than positive diagnosis

• Patients indulge in “doctor shopping” to solve their problems

• Level of satisfaction with traditional therapy is relatively high in some markets -

Confidential

9

Consumer Segmentation & Targets

Extremely Bothered & Dissatisf ied

Social ly Inhibited/Low Esteem

Open & Pro-ActivePosit ive Natural Treater

Dr./Rx Avoider

Live With It

Source: adapted from global WW Plan

•Target Segments

• Women/ men age 30-50

Confidential

10

Physician Segmentation & Targets

Frustrated &Dissatisf ied

22%

Empathetic

18%

Lifestyle Treater

23%

Live With It

18%

Out Of Touch

19%

Source: Lieberman Research Inc., August 2000

•Target Segments

• GI segment is the primary target

•PCP is the secondary and includes IM/ FM , GP and GYN

Zelmac/Zelnorm Global IBS Brand Book: Feb 04

11


Environment Overview

Confidential

12

Drivers of Prescribing Behavior

• GE specialists are the driving force behind prescription*

• Self medication is generally high§

• Inclusion in Social Security/ insurance affects physicians choices

• Level of satisfaction with fibers and antispasmodics is generally high – this is linked to a high loss of patients to follow up, they do not get feedback when treatment fails

• Traditional therapies are used as first line treatment in most cases this is because they are ingrained in physicians’ mind as the standard of care, perceived as safe, and inexpensive

• Pharmacists dispense cheap brands OTC and influence patients of lower socio-economic class who seek their advise

*Pharmacy feedback and load estimates

§Market research – IPSOS Lebanon

Confidential

13

Key Planning Assumptions: KSA

• Positive uptake from GI segment/ support and buy-in

• No exclusion from the National Insurance List due to relative price

• PR creates public demand – patients gain awareness on availability of new drug on the market

• Introduction in Governmental sector in 2005

Confidential

14

Key Planning Assumptions: Levant

• Positive uptake from GI segment/ support and buy-in

• Inclusion in Social Security in Lebanon

• Improved Zelmac’s value proposition (Exp. From Global data)/ cost effectiveness data

• PR creates public demand – patients gain awareness on availability of new drug on the market

Confidential

15

Key Planning Assumptions

• Please insert free text & data as required & delete this line

Confidential

16

Market share (%)

0

5

10

15

20

25

30

Zelmac 4.0

Duspatalin 23.3 26.6 23.7

S copinal 7.0 8.7 9.1

B uscopan 11.6 8.4 8.0

Duphalac 7.6 7.4 7.6

Agiolax 5.8 5.9 6.3

MAT/June 02 MAT/June 03 Es t 2004

Market Share & Share of Voice: CPO KSA

• Source: IMS Sales PADDS and CAM Promotional expenditure

SOV( %)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

Zelmac 0.0% 0.0% 40.4%

Duspatalin 83.0% 83.0% 49.6%

Duphalac 17.0% 17.0% 10.0%

2002 2003 2004

•Data on SOV is incomplete

Confidential

17

Market share (%)

0

2

4

6

8

10

12

14

16

18

20

Duphalac 14.3 15 18.2

B uscopan 18.6 18.9 16.4

Duspatalin 15.1 15.7 15.9

Zelmac 0 1.2 6.3

Dulcolax 9.3 9.3 7

MAT/June 02 MAT/June 03 MAT /June 04

Market Share & Share of Voice: CPO GULF

• Source: IMS Sales PADDS and CAM Promotional expenditure

SOV( %)

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

0.4

0.45

Duphalac 19.3% 18.0%

B uscopan 25.6% 12.0%

Duspatalin 38.6% 26.0%

Zelmac 0.0% 26.0%

Dulcolax 2.9% 18.0%

MAT/June 03 MAT/June 04

•Key takeaways:

Gain has been primarily from Buscopan and Dulcolax

Confidential

18

Market share (%)

0

2

4

6

8

10

12

14

Duphalac 10.9 12 11

Duspatalin 12.2 9 9

B uscopan 9.6 7 7

Dulcolax 6.6 6 7

Zelmac 0 0 3

Mat June 02 Mat June 03 Mat June 04

Market Share & Share of Voice: Lebanon

SOV( %)

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

Dulcolax 19.3% 19.6%

Dusptalin 25.0% 33.0%

Duphalac 17.0% 17.0%

B uscopan 8.0% 9%

Zelmac 0.0% 22.00%

MAT/June 03 MAT June 04

•Solvay is by far the most established in the Market with two brands they hold position 1 and 2

•Highly fragmented market and most drugs are OTC /used in other indications

•SSRI are widely promoted in IBS- not considered in the Market Place

Confidential

19Source of BusinessFrom Where Do We Gain & to Whom Do We Lose Patients

• Main Business today comes from GI specialists – decision is made based on disease severity and sensitivity to price

• The main reason for loss of Rx is price followed by the natural tendency of IBS patients to stop medications (waxing and waning nature)

• We loose patients either to no therapy or cheaper alternatives ( Duspatalin , Librax, etc) that are given off the counter-

• Source: local panel as available

Confidential

20

Competitor Analysis Summary

Products

Key Messages

Antipsam

odics:Dice

tel/Duspatalin

Laxatives: non-soluble

Digestive E

nzymes

Tricyclic A

ntidepressants

SS

RI: C

ipram

Prozac

Laxatives

Effective on all the pain and bloating

Effective on BM’s and consistency

Safe and tolerable

Convenient NA

Improves overall well- being

Compelling and extensive

evidence

Clear and extensive

evidence

Clear butnon extensive

evidence

Negative evidence

Weak or fragmented

evidence

Confidential

21

Perceived Differential Advantage Analysis

Product Differential advantage

Current gap/ perception Ability to Influence

Works on all three symptoms (ABC)

A large proportion of MD’s feel that they have to focus on the most annoying symptom and treat, most int. guidelines support the approach

Medium

Works on the underlying reason for the condition

Support for effect on pain is weak and complicated

Medium

Safe Last FDA update has caused some doubts on safety

High

22


Source:

JNC7, AHA Heart & Stroke Update, Pfizer Facts, Datamonitor

Synthesized by GMIA, Basel

Patient Flow

Confidential

23

ME – Patient Flow Summary (Part I)

80,000 IBS80,000 IBSC-IBS C-IBS 80,000 IBS80,000 IBSC-IBS C-IBS

50,000 pts50,000 ptsD-IBSD-IBS50,000 pts50,000 ptsD-IBSD-IBS

175,000175,000Seek medicalSeek medicalHealthHealth

175,000175,000Seek medicalSeek medicalHealthHealth

525,000 525,000 Do not seekDo not seekMedical Medical healthhealth

525,000 525,000 Do not seekDo not seekMedical Medical healthhealth

150,000 pts150,000 ptsAlternativeAlternativeMedicineMedicine

150,000 pts150,000 ptsAlternativeAlternativeMedicineMedicine

150,000150,000Consult Consult pharmacypharmacy

150,000150,000Consult Consult pharmacypharmacy

700,000700,000 patients patients Aware of IBSAware of IBS

700,000700,000 patients patients Aware of IBSAware of IBS

700,000700,000 Patients Patients unawareunaware

700,000700,000 Patients Patients unawareunaware

1.4 mio1.4 mioPotential FPotential Fpatientspatients

1.4 mio1.4 mioPotential FPotential Fpatientspatients

9.37 mio9.37 mioFemalesFemales9.37 mio9.37 mioFemalesFemales

11.9 mio11.9 mioMaleMale11.9 mio11.9 mioMaleMale

IBS proneIBS pronePopulation Population In ME In ME (adult (adult population)population)

IBS proneIBS pronePopulation Population In ME In ME (adult (adult population)population)

600,000600,000potential ptspotential pts600,000600,000potential ptspotential pts

21.1 mio Adults

45,000 pts45,000 ptsA-IBSA-IBS45,000 pts45,000 ptsA-IBSA-IBS

GE

GP

FM/ IM

225,000225,000Suffer in Suffer in SilenceSilence

225,000225,000Suffer in Suffer in SilenceSilence

120,000 120,000 DrugDrugTreatedTreated

120,000 120,000 DrugDrugTreatedTreated

30,000 30,000 Referred Referred To DocsTo Docs

30,000 30,000 Referred Referred To DocsTo Docs

All CPO’s major countries included: KSA,UAE,Lebanon, Jordan, Kuwait

Key GO

Secondary GO

Confidential

24

80,000 IBS80,000 IBSC-IBS C-IBS 80,000 IBS80,000 IBSC-IBS C-IBS

50,000 pts50,000 ptsD-IBSD-IBS50,000 pts50,000 ptsD-IBSD-IBS

45,000 pts45,000 ptsA-IBSA-IBS45,000 pts45,000 ptsA-IBSA-IBS

50,00050,000Diagnosed Diagnosed 50,00050,000Diagnosed Diagnosed

30,000 30,000 Mis-Mis-diagnoseddiagnosed

30,000 30,000 Mis-Mis-diagnoseddiagnosed

40,000 Drug40,000 DrugTreatedTreated40,000 Drug40,000 DrugTreatedTreated

10,000 No 10,000 No DrugDrugManagementManagement

10,000 No 10,000 No DrugDrugManagementManagement

15,000 15,000 satisfiedsatisfiedWith currentWith currentMedicationMedication

15,000 15,000 satisfiedsatisfiedWith currentWith currentMedicationMedication

25,000 dis25,000 disSatisfied dueSatisfied dueTo efficacyTo efficacyOr tolerabilityOr tolerability

25,000 dis25,000 disSatisfied dueSatisfied dueTo efficacyTo efficacyOr tolerabilityOr tolerability

Antispamodics

Laxatives

Antiflatulents

SSRI/ TCA

4,000 Seek4,000 SeekOther medicalOther medicalOpinionOpinion

4,000 Seek4,000 SeekOther medicalOther medicalOpinionOpinion

4,0004,000Do not seek Do not seek OtherOther opinionopinion

4,0004,000Do not seek Do not seek OtherOther opinionopinion

ME – Patient Flow Summary (Part II)

15,000 seek15,000 seekOther Other MedicalMedical opinionopinion

15,000 seek15,000 seekOther Other MedicalMedical opinionopinion

10,000 do10,000 doNo SeekNo SeekOther medicalOther medicalOpinionOpinion

10,000 do10,000 doNo SeekNo SeekOther medicalOther medicalOpinionOpinion

6,0006,000CompliantCompliant6,0006,000CompliantCompliant

9,0009,000Non-Non-compliantcompliant

9,0009,000Non-Non-compliantcompliant

10,000 pts10,000 ptsRe-seekRe-seekMedicalMedicalopinionopinion

10,000 pts10,000 ptsRe-seekRe-seekMedicalMedicalopinionopinion

20,000 pts20,000 ptsDo not Do not re-seekre-seekMedicalMedical opinionopinion

20,000 pts20,000 ptsDo not Do not re-seekre-seekMedicalMedical opinionopinion

Confidential

25

SWOT Analysis

Strengths

• Evidence of efficacy on multiple symptom relief – 3 symptoms / 1 drug for the treatment of IBS

• Only product to demonstrate some evidence for effects on bloating

• Rapid onset of effect

• MoA linked to pathophysiology of IBS

• Partial agonist – reduces risk of extreme SE

• High level of patient satisfaction once treated

• Good safety and tolerability profile lack of SAEs

• safety in D-IBS demonstrated

Weaknesses

• Perceived safety concerns related to delay in FDA approval

• Weak evidence to link MoA to pathophysiologyy of IBS

• Weak evidence in abdominal pain and bloating

• High placebo response rates in studies

• Marginal efficacy delta from placebo

• perceived poor risk/benefit

• Limited evidence in males and IBS-A

• Limited evidence in alternators

• Lack of active comparator data

Opportunities

• Large patient pool with high level of unmet clinical needs

• Large non presenting patient pool

• First in market. Entry advantage can shape the category by establishing symptom based approach

• Lack of ownership of science of IBS

• IBS patients are currently poorly managed

• Unexplored potential for suppressive therapy in IBS

Threats

IBS is viewed as a non-serious condition thus ‘costly” treatment is avoided

Insurance companies will most likely try to reduce/control prescription

Treatment period- remains unclear or inreasonable

Confidential

26

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

27

Physician & Patient Key Insights – IBS-C: Summary

Patients: Want to feel better but are frustrated• IBS has a negative impact on patients’ quality of life• Existing treatments do not provide satisfactory relief because they may only address one symptom, may worsen

others• Patients are frustrated with their IBS because doctors do not take them seriously

• Physicians do not perceive IBS as a serious condition• Due to their lack of understanding of IBS, physicians are uneasy identifying and diagnosing. This can be time-consuming• Combinations of existing treatments are generally ineffective and this causes patients to repeatedly visit their physician• Physicians feel they are unable to provide IBS-C patients with satisfactory relief

Physicians: Frustrated when diagnosing and treating IBS

• Reinforce that IBS is a “serious” condition that has a significant impact (IMPACT MEDIUM TO HIGH)• Facilitate open communication between patient and physician to develop common/comfortable language that enables

diagnosis through education (IMPACT LOW)• Differentiate on multi-symptom relief (ABCs and MOA)• Continue to emphasize the superiority of Zelnorm in providing satisfactory relief

• Mitigate stigma associated with IBS and reinforce that IBS is a “real” condition that has a significant impact• Continue to emphasize the superiority of Zelnorm and drive additional patient demand via DTC/DTP• Facilitate open communication between patient and physician

Confidential

28

From local insights

• Specialists satisfaction with Traditional Rx is high due to loss to follow up

• Combination therapy is a common choice for GE specialists

• Patients rely heavily on self medication (see back up slide)

• Doctors do not initially believe that IBS affects the quality of life of patients suffering from IBS

• Doctors tend to place patients in mild- moderate or severe IBS based on the patient’s perception of his/ her condition

Confidential

29

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

30

Growth Opportunities & Key Issues

Growth opp. Issue Priority

1. Increase Z use in presenting patients by reinforcing product safety (IBS-C, and CC, off-label use in males)

A. Zelmac differentiation vs. competition and strength of the value proposition 1

B. Poor adherence to dosing and dosing regimen (strengthening product efficacy on ABCs), mainly driven by the price of the drug and nature of the condition

C. physician recognition and diagnosis of IBS patients (MoA, Safety, Efficacy).

D. IBS is not recognised as a legitimate condition. Willingness to prescribe an “expensive” brand

E. Recognition of appropriate Z patients

F. CC Label not to be extended to CH

Confidential

31

Growth Opportunities & Key Issues

Growth opp. Issue Priority

2. Geographic expansion: maximise opportunity in KSA, Kuwait, Jordan and rest of Pharma Services

Optimization of current Field Force structures to allow for launch 2

Price sensitivity in smaller markets/ limits prescription

3. Increase volume patients via DTP-DTC/ Rely on PR

A. Understanding key triggers for the DTC, ( PCP& GI must be 80% on board to be able to recommend/prescribe Zelmac for appropriate sufferers)

3

B. Low IBS and Z awareness among sufferers, low motivation to consult specialistsc. Limited Reach of PR and heavy investment needed for DTC

4. Expand CC/FD/GERD

A. Consolidate in lower GI by launching Z into chronic constipation. CC not seen as an FGD

4

B. Prepare the upper GI market for future indications in FD, GERD and diabetic gastropathy. High barriers to entry and well entrenched competitors

C. Functional dyspepsia currently managed and diagnosed as GERD patients

Future GO’s based on Indications

Confidential

32

Growth Opportunities: Top Line Maximization

Growth Opportunity Potential Marketing Mix elements

Patients presenting at GI level

High GI QOL study

Pan Arab Congress

Stand Alone/ UEGW?

FF visits

Patients presenting at PCP level

Medium Educational series

ME Workshop

FF visits

Patients unaware of condition or new treatments

High PR Campaign

Off- label use in CC and other indications

Medium NA – Limited

Confidential

33

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

34

Goal:1st line Rx Treatment for IBS-C

Symptom based approach to rapidly penetrate & expand toSymptom based approach to rapidly penetrate & expand to

several GI markets (IBS, CC, Dyspepsia, GERD)several GI markets (IBS, CC, Dyspepsia, GERD)Where We Are Today: The latest advancement in IBS-C

Where We Want to Be:The 1st Line Rx treatment for

functional GI disorders

Differentiate Z as first line Rx treatment vs.competition

Increase awareness on disease area and know –how at PCP level

Swiss approval in CC for ability to push indication

Successful launch in KSA

In IBS-C, Zelmac is the most effective first l ine Rx treatment for IBS-C abdominal pain, bloating,

constipation (ABCs) because it is the only drug that regulates motil ity, visceral sensitivity, and intestinal

secretion throughout the GI tract

Strengthen Z’s value proposition

Establish KOL base

Governmental introduction and inclusion in major LPO

LN Social Security inclusion

Confidential

35

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

36

A-to-B Shift Strategy: IBS (MDs)

Physician does not recognize IBS

Physician does not proactively diagnose IBS-C

Physician diagnoses IBS-C and treats with diet/lifestyle and single-symptom therapies

Physician uses Zelmac first-line for all appropriate patients

STEP # 1

STEP # 2

STEP # 3

STEP # 4

Physician uses Zelmac in some, not all, appropriate patients

Confidential

37

A BSuggested location in the Zelmac Global A-B

Marketing Mix by target segment in the Global A-B

These doctors are sceptical of this syndrome and consider it as psychosomatic condition

Call Objective Profiling patients and diagnosis tools- link to the impact on QOL and supporting data

Patient profilesStep 1 - Patient profile needs to be linked to Disease Diagnosis- Outline Step 2 - those whose quality of life has been impacted and need medical care

This disorder really impacts ME people and affects their QOL

SI 4QOL Epidemiological Study

Learning the Art of dealing with this group of patients- Diet and lifestyle and patient care

SI1Educational Series

Real medical disorder, prevalent, associated with ABC, serotonin implicated, burden on sufferers and society

SI 1ME IBS Workshop

MessageLink to SIActivity*

Target segment description: Physician does not recognise IBS

Confidential

38


Marketing Mix by target Segment in the Global A-B

Physician refers ‘query-IBS-C’ patients to a specialist; worries they will misdiagnose organic disease; only gives a diagnosis of IBS-C after ruling out all other diseases

Call Objective Positive Diagnosis is possible

Patient profiles IBS-C patients

Rome II criteria, case studies Increase awareness on disease area

Dinner meetings/ Local events

Rome II criteria , a course in GIT to help deal with IBS in the end of the day

Increase awareness on disease area

Educational Series

Safe, confident, positive diagnosis possible through Identify, probe, eliminate

ME IBS Workshop


Target segment description: Physician does not proactively diagnose IBS-C

Increase awareness on disease area and know –how at PCP level

Confidential

39



Physician diagnoses IBS-C and treats with diet/lifestyle and single-symptom therapies

Call ObjectivePersuade the doctor that although diet/lifestyle changes are important many patients still rely on medication for global symptom relief


No single agent can relieve the overall symptoms except Zelmac that can manage the ABC

S 1& 3Dinner meetings/ Local events

Learning the Art of dealing with this group of patients

S1 & S5Educational Series

Patients need Diet/life style changes in addition to medical treatment in most

SI 4FF Calls- Pt. Educational materials



Confidential

40



Physicians prescribe for some but not all appropriate patients

Call ObjectiveUnderstand the reasons behind not prescribing Zelmac for all patients: three likely options are price, disease severity, or side effect profile / safety (less likely)


The value added by 5HT4 partial agonists extended to all patients

SI 5ME WS / Pan Arab

Samples help start more patients on a good drug and give them a chance for improvement SI 4Sampling

Patients need Diet/life style changesSI 4FF Calls- cost effectiveness date



Confidential

41

C4 Insights Summary



Analysis & SWOT



Key Issues


Brand Strategy

KPI’s

Confidential

42

Calendarized Plan of Personal Promotion Program: CPO KSA

# Universe 1669# Target Doctors 1324

Current Y - # details to target doctors Budget - # details to target doctorsQ1/T1 Q2/T2 Q3/T3 Q4 Q1/T1 Q2/T2 Q3/T3 Q4

P1 310 307 347 363 335P2

P1 Eq.

SOV %

Totals2003 2004 2005

P1 6820 29744P2

P1 Eq.

SOV %

Field Force Productive FrequencyUniverse Tiers Tier Productive 2004 2005

Definition Size Frequency %attainmentGoal MAT Goal

Gastroentero. 113 Tier 1 50 33 95% 100%Tier 2 50 22 95% 100%

IM 1556 Tier 1 266 33 60% 90%Tier 2 958 11 30% 80%

Confidential

43

Calendarized Plan of Personal Promotion Program: Lebanon

# Universe 2930# Target Doctors 475


P1 220 409 500 415 286 286 226 256P2 0.5 1.75 2.25 1.5 0 0 0 0P1 Eq.SOV % 7 10 13 13 13 13 13 13

Totals2003 2004 2005

P1 535 5733 6567P2 1 23 0P1 Eq.SOV % 7 13 13



GE Tier 1 43 22 95% 54% 95%220 Tier 2 122 11 90% 87% 95%

Tier 3

PCP Tier 1 53 22 95% 51% 98%2710 Tier 2 257 11 90% 70% 95%

Tier 3

Confidential

44

Calendarized Plan of Personal Promotion Programs: UAE

# Universe# Target Doctors 355


P1 77 135 132 140 146 150 130 156P2P1 Eq.SOV % 9.5% 17.8% 19.5% 19.5% 19.9% 19.0% 17.0% 19.0%

Totals2003 2004 2005

P1 308 2341 2910P2P1 Eq.SOV % 2.6% 16.6% 18.0%

Field Force Productive Frequency

Universe Tiers Tier Productive 2004 2005


Gasrto 22 Tier 1 10 22% 90% 81% 95%Tier 2 12 11% 80% 76% 90%

IM 101 Tier 1 21 22% 85% 70% 95%Tier 2 80 11% 80% 70% 90%

GPs 232 Tier 1 39 22% 70% 75% 90%Tier 2 293 11% 70% 72% 90%

Confidential

45

Calendarized Plan of Personal Promotion Program: Jordan

# Universe 1063 including GI, GPs, Ims & FMs# Target Doctors 80 04,05


P1 66 108 315 315 315 290P2P1 Eq.SOV %

Totals2003 2004 2005

P1 174 1235P2P1 Eq.SOV %



GE 36 Tier 1 15 26 7% 95%Tier 2 21 12 3% 90%Tier 3

PCP Tier 1 10 24 95%Tier 2 34 12 90%Tier 3

Confidential

46

Calendarized Plan of Promotion Programs

YEAR: 2005

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

ME Workshop • 15 docs Levant ,32 KSA, 10 Ro Gulf

Pan Arab- Lebanon • 150 docs Levant , 25 KSA, 10 Ro Gulf

PMS Study/ QOL study

Stand Alone meeting

PR Activity • Patient education and coverage

Cancelled

PMS in KSA

QOL study in Levant and Ro Gulf

C4 local brand_plan_zelmac2

Documents

Transcript of C4 local brand_plan_zelmac2